Table 1 Baseline epidemiologic and clinical characteristics of the GACRS cohort

Gender

 Male

166 (59.7%)

160 (57.8%)

0.704

 Female

112 (40.4%)

117 (42.2%)

Age (years)

 Mean (SD)

9.02 (1.81)

8.99 (1.87)

0.858

 Median [Min, Max]

8.72 [5.44, 14.2]

8.67 [6.02, 15.2]

BMI

 Mean (SD)

18.3 (4.06)

17.8 (3.62)

0.12

 Median [Min, Max]

17.2 [12.6,41.4]

16.8 [11.3,35.0]

Bronchodilator Response as % of baseline FEV1

 Mean (SD)

-3.82 (3.74)

17.6 (11.5)

< 0.001

 Median [Min, Max]

-2.81 [-24.6, 0.131]

14.0 [8.75, 89.7]

% predicted Pre-BD FEV1

 Mean (SD)

106 (16.7)

88.5 (16.4)

< 0.001

 Median [Min, Max]

106 [34.6, 180]

89.1 [31.8, 131]

Pre-BD FEV1/FVC

 Mean (SD)

87.7 (6.97)

79.0 (9.20)

< 0.001

 Median [Min, Max]

87.5 [40.5,100]

79.5 [50.6,100]

Log10 Eosinophil

 Mean (SD)

2.54 (0.414)

2.70 (0.375)

< 0.001

 Median [Min, Max]

2.63 [1.00, 3.35]

2.76 [1.00, 3.41]

 Missing

9 (3.2%)

6 (2.2%)

Blood Eosinophil Count (cells/µl)

 Mean (SD)

493 (374)

672 (464)

< 0.001

 Median [Min, Max]

430 [10.0, 2220]

570 [10.0, 2580]

 Missing

9 (3.2%)

6 (2.2%)

Vitamin D (ng/ml)

 Mean (SD)

38.3 (12.4)

37.3 (13.1)

0.52

 Median [Min, Max]

37.8 [16.6, 98.1]

35.7 [16.6, 97.7]

 Missing

137 (49.6%)

129 (46.6%)

Airway hyper-responsiveness

 Mean (SD)

2.36 (2.69)

1.43 (2.17)

< 0.001

 Median [Min, Max]

1.40 [0.104, 15.5]

0.949 [0.0440, 16.6]

 Missing

107 (38.6%)

83 (30.0%)

ICS use history

 No

156(56.1%)

110(39.7%)

< 0.001

 Yes

122(43.9%)

167(60.3%)

GINA Symptom Control Score

 Well controlled (0)

29 (10.4%)

16 (5.8%)

0.048

 Partly controlled (1–2)

77 (27.7%)

66 (23.8%)

 Uncontrolled (3–4)

172 (61.9%)

195 (70.4%)